Market Outlook:

Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease. Increasingly, drug developers are focusing on subsets of first-line CLL patients, such as elderly patients or those who harbor chromosome 17p deletions. The high unmet need for novel therapies with better efficacy and improved safety and tolerability profiles for the therapeutic management of first-line CLL presents notable commercial opportunity for drug developers.

Questions Answered:

  • What are the treatment drivers and goals for first-line CLL? How do current therapies, such as Johnson & Johnson/Janssen/AbbVie’s Imbruvica, perform on these metrics?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What are the prevailing areas of unmet need and opportunity in first-line CLL? Are late-phase emerging therapies targeting these areas?
  • What trade-offs are surveyed hematological oncologists willing to make across different key clinical attributes and price, when considering hypothetical new treatment options in first-line CLL?

Production Description: Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Unmet Need - Detailed, Expanded Analysis (First-Line Chronic Lymphocytic Leukemia)
    • Treatment Drivers and Goals
      • Overview
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Physician Rating of Treatment Drivers and Goals in First-Line Chronic Lymphocytic Leukemia
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: Europe
      • Stated vs. Derived Importance of Treatment Drivers and Goals
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in First-Line Chronic Lymphocytic Leukemia: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products/Regimens for First-Line Chronic Lymphocytic Leukemia
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia: United States
        • Overall Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia: Europe
        • Relative Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Hematological Oncologists’ Satisfaction with the Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Hematological Oncologists’ Satisfaction with the Performance of Key Therapies for First-Line Chronic Lymphocytic Leukemia on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Physician Rating of Unmet Need in Chronic Lymphocytic Leukemia
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Chronic Lymphocytic Leukemia: United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Chronic Lymphocytic Leukemia: Europe
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Chronic Lymphocytic Leukemia: United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Chronic Lymphocytic Leukemia: Europe
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Chronic Lymphocytic Leukemia: United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Chronic Lymphocytic Leukemia: Europe
      • Unmet Need in First-Line Chronic Lymphocytic Leukemia and Related Indications
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need in First-Line Chronic Lymphocytic Leukemia and Related Indications: United States
        • Surveyed Hematological Oncologists' Ascribed Level of Unmet Need in First-Line Chronic Lymphocytic Leukemia and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the First-Line Chronic Lymphocytic Leukemia Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy with Improved Overall Survival
        • Opportunity: A Novel Therapy That Improves Progression-Free Survival
        • Opportunity: A New Therapy That Offers Substantial Improvement in Complete Response
        • Opportunity: A Novel Therapy with a More-Favorable Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • First-Line Chronic Lymphocytic Leukemia Target Product Profile: Attribute Importance
        • Median Progression-Free Survival
        • Objective Response Rate
        • Complete Response
        • Incidence of Any Grade Diarrhea
        • Incidence of Grade 3/4 Infections
        • Incidence of Grade 3/4 Neutropenia
        • Price per Cycle of Treatment
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Target Product Profiles Included in Scenario 1
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Target Product Profiles Included in Scenario 2
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 3
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 3
        • First-Line Chronic Lymphocytic Leukemia Market Simulations: Target Product Profiles Included in Scenario 3
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, M.Pharm., Ph.D., is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her Ph.D. research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at G.J. University of Science & Technology, Hisar, India.


Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-y...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details